Financial Performance - For the year ended December 31, 2025, net revenue was approximately $1.2 million, a significant increase from $135 thousand in 2024, reflecting the first full year of QUELIMMUNE product sales[13] - For the three months ended December 31, 2025, net revenue was approximately $420 thousand, comprised of $315 thousand from QUELIMMUNE therapy sales and $105 thousand from SCD sales[6] - The company reported net revenue of $420,000 for the three months ended December 31, 2025, compared to $67,000 for the same period in 2024, representing a significant increase of 527%[38] - SeaStar Medical anticipates achieving approximately $2 million in net product revenue in 2026, with plans to broaden QUELIMMUNE adoption to include 15 additional top-ranked children's medical centers[12] Clinical Trials and Product Development - The company achieved over 50% enrollment in the NEUTRALIZE-AKI pivotal trial, with 181 out of 339 patients enrolled to date[4] - QUELIMMUNE therapy demonstrated a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90, indicating a nearly 50% reduction in loss of life compared to historical data[25] - SeaStar Medical is conducting the NEUTRALIZE-AKI pivotal clinical trial for its SCD therapy, targeting over 200,000 adults in the U.S. annually who suffer from AKI[30] - The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation from the FDA for six therapeutic indications, potentially expediting the approval process[30] - SeaStar Medical's first commercial product, QUELIMMUNE (SCD-PED), was approved by the FDA in 2024, specifically for life-threatening Acute Kidney Injury (AKI) in critically ill pediatric patients[30] Expenses and Losses - Research and development expenses decreased to $7.5 million in 2025 from $9.1 million in 2024, primarily due to declines in personnel and consulting costs[15] - General and administrative expenses decreased to approximately $5.9 million in 2025 from $8.9 million in 2024, attributed to reduced personnel and consulting-related fees[16] - Total operating expenses for the year ended December 31, 2025, were $13.36 million, down from $17.98 million in 2024, indicating a reduction of approximately 25%[38] - SeaStar Medical's net loss for the year ended December 31, 2025, was $12.15 million, compared to a net loss of $24.83 million in 2024, reflecting a 51% improvement[38] Financial Position - The cost of goods sold for the year ended December 31, 2025, was $53 thousand, with a gross margin greater than 90% for the quarter ended December 31, 2025[14][7] - The company improved its balance sheet by adding approximately $23.9 million in capital during 2025 and reducing operating liabilities by $3.1 million[4] - Cash as of December 31, 2025, was $12.0 million, compared to $1.8 million as of December 31, 2024[19] - The company has cash reserves of $11.98 million as of December 31, 2025, a significant increase from $1.82 million at the end of 2024[36] - SeaStar Medical's total assets increased to $14.16 million as of December 31, 2025, compared to $4.66 million in 2024, marking a growth of 203%[36] Market Strategy - The company aims to broaden QUELIMMUNE adoption by partnering with top-ranked children's medical centers, enhancing market penetration[32]

Financial Performance - Total revenues for the full year 2025 increased 1.4% to a record $12.7 million compared to $12.5 million in 2024[3][23] - Same-store revenues for the full year 2025 increased 1.4% to a record $12.6 million compared to $12.5 million in 2024[25] - Same-store net operating income (NOI) for the full year 2025 increased 0.6% to $7.8 million compared to $7.7 million in 2024[26] - Net income for the full year 2025 was $2.0 million or $0.18 per diluted share, compared to $2.1 million or $0.19 per diluted share in 2024[27] - Funds from operations (FFO) for the full year 2025 increased 2.7% to $4.0 million or $0.36 per diluted share compared to $3.9 million or $0.35 per diluted share in 2024[28] - Adjusted funds from operations (AFFO) for the full year 2025 increased 3.4% to $4.4 million or $0.39 per diluted share compared to $4.3 million or $0.38 per diluted share in 2024[28] - The net income for the three months ended December 31, 2025, was $322,824, compared to $84,406 for the same period in 2024, indicating a significant increase of approximately 282%[43] - The company reported a basic earnings per share of $0.18 for the year ended December 31, 2025, consistent with the previous year[43] Assets and Liabilities - Total assets decreased to $64,072,646 as of December 31, 2025, from $65,515,024 in 2024, reflecting a decline of approximately 2.2%[42] - The company's cash and cash equivalents increased to $7,364,963 as of December 31, 2025, compared to $7,180,857 in 2024, marking an increase of about 2.6%[42] - Total liabilities decreased to $17,536,256 as of December 31, 2025, from $18,077,347 in 2024, a reduction of approximately 3%[42] - The company’s accumulated deficit increased to $(3,486,856) as of December 31, 2025, from $(2,235,236) in 2024, indicating a growing deficit[42] Operational Metrics - Same-store occupancy at December 31, 2025, increased 10 basis points to 93.0% from 92.9% at December 31, 2024[20] - The company’s same-store revenues for the three months ended December 31, 2025, were $3,140,574, slightly down from $3,168,391 in 2024, a decrease of about 0.9%[44] - The company’s total expenses for the year ended December 31, 2025, were $9,743,894, compared to $9,635,952 in 2024, an increase of approximately 1.1%[43] Dividends and Strategic Plans - The company maintained a quarterly dividend of $0.0725 per share, consistent with the previous year and quarter, representing an annualized rate of $0.29 per share[5] - The company plans to continue executing its strategic business plan, focusing on acquisitions, joint ventures, and expansion in select markets[6][13]

Financial Performance - Revenue for Q4 2025 was $0, down from $4.4 million in Q4 2024; total revenue for 2025 was also $0, compared to $41.1 million in 2024[4] - R&D expenses for Q4 2025 were $1.5 million, a decrease of 79% from $7.3 million in Q4 2024; total R&D expenses for 2025 were $12.8 million, down 66% from $37.4 million in 2024[5] - G&A expenses for Q4 2025 were $2.4 million, up from $1.8 million in Q4 2024; total G&A expenses for 2025 were $10.8 million, a slight decrease from $11.9 million in 2024[6] - Net loss for Q4 2025 was $3.8 million, or $(0.04) per share, compared to a net loss of $5.8 million, or $(0.16) per share in Q4 2024; total net loss for 2025 was $22.4 million, or $(0.39) per share, compared to a net loss of $8.1 million, or $(0.23) per share in 2024[7] - Total stockholders' equity increased to $28.6 million as of December 31, 2025, compared to $19.1 million in 2024[17] Cash and Financing - Cash, cash equivalents, and short-term investments totaled $30.3 million as of December 31, 2025, up from $22.6 million as of December 31, 2024; the company expects this to fund operations into 2029[8] - The company completed a private placement financing of $35 million in March 2026 and a previous financing of up to $50 million in August 2025, reinforcing confidence in its strategy[3] Product Development - EQ504, a selective AhR modulator, is set to enter a Phase 1 proof-of-mechanism study in mid-2026, with data expected approximately six months thereafter[2] - The company aims to position EQ504 as a best-in-class oral therapy for ulcerative colitis and other inflammatory diseases[2] - The company is also evaluating further advancement of EQ302, an oral bi-specific inhibitor for GI indications, including celiac disease[3]

Financial Performance - Funds from Operations (FFO) for the year ended December 31, 2025, was $16.489 million, compared to $16.802 million in 2024 [243]. - Adjusted Funds from Operations (AFFO) for the year ended December 31, 2025, was $17.238 million, an increase from $14.988 million in 2024 [243]. - Net cash provided by operating activities decreased to $14.967 million in 2025 from $18.241 million in 2024, primarily due to changes in derivative cash settlements [254][255]. - Net cash provided by investing activities increased significantly to $27.801 million in 2025 from $8.395 million in 2024, driven by proceeds from the sale of real estate properties [254][256]. - Rental revenue decreased to $45.8 million in 2025 from $46.5 million in 2024, attributed to lease expirations [258]. - General and administrative expenses decreased by 8% to $5.8 million in 2025 from $6.3 million in 2024, due to reduced headcount and other cost-saving measures [259]. - Stock compensation expense increased by 84% to $2.9 million in 2025 from $1.6 million in 2024, due to the awarding of Class X OP Units [260]. - Depreciation and amortization expense decreased by 9% to $15.1 million in 2025 from $16.6 million in 2024, as a result of changes in property classification [261]. - An impairment charge of $5.8 million was recorded in 2025 related to real estate investment property in Saint Paul, Minnesota, with no such charges in 2024 [263]. - The gain on sale of real estate investments was $2.5 million in 2025, compared to $3.4 million in 2024 [264]. - Other expenses decreased slightly to $15.3 million in 2025 from $15.5 million in 2024, influenced by various factors including insurance claim settlements [265]. Investment Activities - The company sold 212,791 shares of Class C Common Stock in the ATM Offering at an average price of $15.66 per share, generating net proceeds of $3.3 million for the year ended December 31, 2025 [218]. - On March 7, 2025, the company acquired an industrial property for $6.1 million, consisting of $0.3 million in cash and 344,119 Class C OP Units valued at $5.9 million [232]. - The company completed the sale of a property in Endicott, New York for $2.4 million on February 26, 2025, and amended another lease to increase the base rent by $2,500 per month [234]. - The sale of an office property in Issaquah, Washington was completed for $26.0 million, which included $25.6 million in sales price and $0.4 million in extension fees [235]. - The company expects to incur $2.0 million for future on-site and tenant improvements by tenants, to be completed in 2026 [237]. - Total investments in real estate property as of December 31, 2025, were $495.353 million, with $386.975 million in industrial core properties [248]. - The company has identified certain legacy assets for recycling over the next two years, including two office assets and shorter lease duration industrial properties [246]. Debt and Financing - As of December 31, 2025, the Operating Partnership had an approximate 81% interest, with a leverage ratio of 45.1% [205]. - The company entered into three new swap agreements for $250.0 million, fixing the Secured Overnight Financing Rate (SOFR) at 2.45% for the year ending December 31, 2026, resulting in a fixed rate of 4.15% [210]. - The company reported a fixed interest rate of 4.14% on its indebtedness as of March 25, 2026, due to interest rate swap agreements [213]. - The company is subject to financial loan covenants and was in compliance with these covenants as of December 31, 2025 [230]. - As of March 25, 2026, the company had $30.0 million of borrowing capacity available under its Credit Facility, which may be utilized for attractive investment opportunities [216]. Market Outlook - The company anticipates that future declines in economic conditions could negatively impact commercial real estate fundamentals, leading to lower occupancy and rental rates [212]. - The company aims to provide attractive growth in Adjusted Funds from Operations (AFFO) and sustainable cash distributions as part of its investment objectives [209]. Lease and Property Management - The company obtained two lease extensions in 2025, with Fujifilm Dimatix, Inc. extending its lease for ten years and Northrop Grumman Systems Corporation extending its lease for five years [212].

Operating Expenses - Operating expenses for the year ended December 31, 2025, were $24.2 million, an increase of 41% from $17.1 million in 2024[4] - Research and development expenses rose to $13.2 million in 2025, up 76% from $7.5 million in 2024, primarily due to increased clinical activities and headcount[5] - General and administrative expenses increased to $11.0 million in 2025, compared to $9.6 million in 2024, reflecting higher stock-based compensation and consulting expenses[8] Financial Performance - The net loss attributable to Serina common stockholders for 2025 was $19.4 million, or $(1.91) per share, compared to a net loss of $11.1 million, or $(1.51) per share in 2024[10] - Total revenues for 2025 were $130,000, up from $56,000 in 2024, primarily from grant revenues[25] Cash and Cash Equivalents - Cash and cash equivalents totaled $3.1 million as of December 31, 2025, down from $3.7 million in 2024[11] - The net decrease in cash and cash equivalents was $(616) million in 2025, a significant improvement compared to $(3,947) million in 2024[27] - Cash and cash equivalents at the beginning of the year were $3,672 million, while at the end of the year, they decreased to $3,056 million[27] Financing Activities - Serina secured up to $30 million in new financing, with $16 million received as of March 23, 2026[2][7] - The company initiated an At-the-Market (ATM) equity program, raising $10 million from the sale of 3 million shares at an average price of $3.36 in 2026[7] - Net cash provided by financing activities increased significantly to $17,412 million in 2025 from $13,212 million in 2024, showing stronger financing support[27] Asset Management - Total assets as of December 31, 2025, were $6.951 million, compared to $6.724 million in 2024[23] Cash Flow Analysis - Net cash used in operating activities increased to $(17,955) million in 2025 from $(17,137) million in 2024, reflecting a decline in operational efficiency[27] - Net cash used in investing activities rose to $(59) million in 2025 compared to $(22) million in 2024, indicating increased investment expenditures[27] - The effect of foreign currency on cash and cash equivalents resulted in a decrease of $(14) million in 2025, highlighting currency impact on cash flow[27] Regulatory Milestones - The FDA granted IND clearance for SER-252, with the first patient dosed in a Phase 1 registrational trial for advanced Parkinson's disease[6][7]

Financial Performance - For the year ended December 31, 2025, Serina Therapeutics reported operating expenses of $24.2 million, an increase of 41.2% from $17.1 million in 2024[4]. - The net loss attributable to Serina common stockholders for 2025 was $19.4 million, or $(1.91) per share, compared to a net loss of $11.1 million, or $(1.51) per share in 2024, reflecting a 74.8% increase in losses[10][25]. - Total revenues for 2025 were $130,000, a significant increase from $56,000 in 2024, primarily from grant revenues[25]. Expenses - Research and development expenses rose to $13.2 million in 2025, up 76% from $7.5 million in 2024, primarily due to increased clinical activities and headcount[5]. - General and administrative expenses increased to $11.0 million in 2025, compared to $9.6 million in 2024, driven by higher stock-based compensation and consulting expenses[8]. Cash and Cash Equivalents - As of December 31, 2025, cash and cash equivalents totaled $3.1 million, down from $3.7 million in 2024[11][23]. - Cash and cash equivalents at the beginning of the year were $3,672 million in 2025, down from $7,619 million in 2024[27]. - Cash and cash equivalents at the end of the year decreased to $3,056 million in 2025 from $3,672 million in 2024, marking a decline of 16.8%[27]. - The net decrease in cash and cash equivalents was $(616) million in 2025, a significant improvement compared to $(3,947) million in 2024[27]. Financing Activities - Serina secured up to $30 million in new financing, with $16 million received as of March 23, 2026, to support clinical milestones[2][7]. - Net cash provided by financing activities increased to $17,412 million in 2025, up from $13,212 million in 2024, representing a growth of 31.5%[27]. Investment Activities - Net cash used in investing activities rose to $(59) million in 2025 compared to $(22) million in 2024, indicating a significant increase in investment spending[27]. Clinical Development - The company initiated a Phase 1b trial for SER-252 in advanced Parkinson's disease, with the first patient dosed in February 2026[7][15]. Assets - The total assets of Serina as of December 31, 2025, were $6.951 million, compared to $6.724 million in 2024[23]. Strategic Partnerships - The company plans to advance additional applications of its POZ platform through out-licensing and partnerships, including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery[14].

Financial Performance - The company reported a net loss of $35,444,361 for the year ended December 31, 2025, compared to a net loss of $11,155,516 for the previous year, representing an increase of 217.5%[400] - Cash used in operating activities was $22,776,769 for the year ended December 31, 2025, compared to $10,247,231 for the previous year, indicating a significant increase in operational spending[425] - The company has an accumulated deficit of $64,348,118 as of December 31, 2025, compared to $28,903,903 at the end of 2024[411] - The company expects to continue incurring significant operating losses for the foreseeable future and may never become profitable[409] Operating Expenses - Total operating expenses for 2025 reached $34,359,302, a significant increase from $11,180,902 in 2024, representing a 208% rise[399] - Research and development (R&D) expenses increased by $4,193,650 or 118.9% for the year ended December 31, 2025, primarily due to increased clinical trial activity for SKNJCT-003, SKNJCT-004, and Teverelix[403] - General and administrative expenses rose by $10,267,275 or 134.2% for the year ended December 31, 2025, mainly due to increased salaries and wages from a higher headcount[401] Financing Activities - The Company raised $4.0 million from its initial public offering by selling 970,000 units at $4.125 per unit[388] - The Company completed a Regulation A Offering, raising $4.2 million from the sale of 1,490,000 units at $2.80 per unit[390] - Cash flows provided by financing activities were $31,939,785 for the year ended December 31, 2025, compared to $12,692,216 for the previous year, reflecting increased proceeds from equity offerings and other financing[426] - The company entered into a Standby Equity Purchase Agreement (SEPA) allowing it to sell up to $15,000,000 of common shares to Yorkville over 36 months, with conditions for execution[419] - The company has entered into an equity distribution agreement to sell up to $15.3 million of common shares as part of an at-the-market program[398] Clinical Studies - The SKNJCT-003 Phase 2 clinical study demonstrated more than 60% clinical clearance in an interim analysis after over 50% of the targeted 60 patients were randomized[376] - The Company has initiated a clinical study (SKNJCT-002) but ultimately closed it without further enrollment due to variability in array application, with no adverse events reported[374] - The Company received approval from the UAE Department of Health to commence clinical study SKNJCT-004, which will randomize 36 patients across four clinical sites[377] Acquisitions - The Company completed the acquisition of Antev for approximately $2.97 million in cash and 1,603,164 common shares, acquiring 98.6% of Antev's outstanding shares[378] - The company accounts for business combinations using the acquisition method, recording any excess purchase price over fair values of net assets as goodwill[434] - For asset acquisitions, costs are allocated to identifiable assets and liabilities based on relative fair values, with no goodwill recognized[435] Research and Development - Research and development costs are fully expensed as incurred, primarily consisting of salaries and clinical trial costs[437] - The company accrues estimated research and development costs based on services performed by third-party contractors and clinical trial sites[438] Stock and Shares - As of December 31, 2025, the company had 25,176,303 Common Shares outstanding, with an additional 2,505,000 shares issuable from stock options and 7,281,795 from warrants[444] - Stock-based compensation is expensed over the requisite service period based on estimated grant-date fair value, using the Black-Scholes model[442] Other - The Company incurred total issuance costs of $2.1 million related to its initial public offering, including underwriter fees and legal costs[389] - The company completed a Regulation A Offering of 1,490,000 units at $2.80 per unit, with 1,473,800 warrants exercised for proceeds of $4,126,639 during the year ended December 31, 2025[412] - Fair value measurements include cash and cash equivalents, with the fair value option elected for Initial Debentures, resulting in no gain or loss at issuance[440] - The Company entered into a non-binding memorandum of understanding with Helix Nanotechnologies to develop an advanced mRNA platform[380]

Financial Performance - Net sales for Q3 FY2026 were $926.6 million, an increase of 5.8% year-over-year, with organic growth of 3.8%[4] - Orders reached $931.6 million, up 9.2% as reported and 7.2% organically, driven by growth in North America Contract and Global Retail segments[4] - Gross margin improved to 38.1%, a 20 basis point increase compared to the previous year[4] - Consolidated operating expenses decreased to $308.0 million, down 25.7% year-over-year[4] - Operating margin for Q3 was 4.8%, a significant improvement from a negative margin of 9.4% in the prior year[4] - Earnings per share (diluted) were $0.34, compared to a loss of $0.19 in the same quarter last year, representing a 278.9% increase[4] - Adjusted operating earnings for the entire company reached $53.2 million, with an adjusted operating margin of 5.7%[34] - Diluted earnings per share for the three months ended February 28, 2026, was $0.34, compared to a loss of $0.19 for the same period last year, with adjusted earnings per share at $0.43[35] - Net sales for the nine months ended February 28, 2026, were reported at $2,837.5 million, reflecting a 4.8% increase from the previous year[41] Cash Flow and Liquidity - Cash flow from operations was $61.1 million, slightly down from $62.1 million in Q3 last year[9] - As of February 28, 2026, liquidity was $594.0 million, including cash on hand and available credit[9] - Cash and cash equivalents decreased to $174.6 million from $193.7 million, reflecting a tighter liquidity position[19] Segment Performance - Net sales for the North America Contract segment reached $488.6 million, a 4.5% increase from $468.2 million in the same period last year[33] - Adjusted operating earnings for the North America Contract segment improved to $47.8 million, representing a 9.8% operating margin, up from 9.1%[33] - Global Retail segment net sales increased to $281.1 million, with an operating earnings of $6.3 million, a significant recovery from a loss of $94.4 million in the previous year[33] - Organic sales growth for the three months ended February 28, 2026, was 4.1% in North America Contract and 7.1% in Global Retail, leading to a total organic growth of 3.8%[40] Assets and Liabilities - Total assets increased slightly to $3,951.6 million as of February 28, 2026, compared to $3,950.2 million on May 31, 2025[19] - Total liabilities decreased to $2,553.2 million from $2,615.1 million, indicating improved financial health[19] - Goodwill increased to $1,167.2 million, up from $1,152.4 million, indicating potential growth through acquisitions[19] Operational Changes - New store openings included two DWR stores and a Herman Miller store, contributing to market expansion efforts[14] - The total store count increased to 89 locations in Q3 FY2026, up from 78 in Q3 FY2025, with total square footage reaching 559,249 thousand[46] - The company incurred restructuring charges of $2.2 million in the latest quarter, consistent with previous periods[34] Future Outlook - The company expects Q4 FY2026 net sales to be between $955 million and $995 million, with an adjusted earnings per share forecast of $0.49 to $0.55[12] - The consolidated backlog for MillerKnoll as of Q3 FY2026 was $711.6 million, an increase from $686.4 million in Q3 FY2025[45] Risks and Challenges - The company faces risks from geopolitical instability, particularly in the Middle East, which may negatively impact supply chains and sales[50] - Changes in U.S. and international trade policies could affect material costs and product demand, impacting overall financial performance[50] - Consumer spending levels significantly influence demand within MillerKnoll's Global Retail segment, highlighting the importance of economic conditions[50] - The ongoing conflict in the Middle East and the Russia-Ukraine war contribute to heightened inflation and economic uncertainty, affecting business operations[50] - MillerKnoll's acquisition of Knoll has resulted in additional debt, increasing interest expenses and imposing limitations on certain business activities[50] - Cybersecurity threats and public health crises, such as pandemics, pose risks to operational stability and financial performance[50] - The company is monitoring the availability and pricing of raw materials, which are critical for manufacturing its products[50] - Financial strength of dealers and customers is essential for maintaining sales and revenue growth[50] - The pace of government procurement and outcomes of pending litigation may also impact MillerKnoll's business operations and financial outlook[50]

Clinical Development - NKX019 is currently in Phase 1 clinical trials for lupus nephritis and primary membranous nephropathy, as well as for systemic sclerosis, myositis, and ANCA-associated vasculitis[19]. - The company is currently enrolling patients in two Phase 1 clinical trials, Ntrust-1 and Ntrust-2, to evaluate NKX019 for lupus nephritis and systemic sclerosis, respectively[165]. - The Ntrust-1 trial is a multi-center, open-label, dose-escalation study evaluating NKX019's safety and clinical activity in patients with refractory LN, with plans to add pediatric minimal change disease (pMN) as an indication by May 2025[180]. - In June 2024, the FDA also cleared an IND for NKX019 to evaluate its use in treating scleroderma, myositis, and ANCA-associated vasculitis (AAV) in the Ntrust-2 clinical trial[181]. - The company has streamlined the enrollment process for clinical trials, allowing combined data review by an independent Data Safety Monitoring Board[23]. - The FDA's Food and Drug Omnibus Reform Act (FDORA) requires sponsors to develop diversity action plans for Phase 3 clinical trials, which may impact the company's clinical development timelines[177]. - The company faces significant competition from other cell therapy companies targeting autoimmune diseases, which may affect enrollment and development timelines for NKX019[190]. - Enrollment challenges in the Ntrust-1 and Ntrust-2 trials have been significant, potentially delaying the clinical development process[183]. - The company may experience delays in clinical trials due to various factors, including regulatory approvals and patient recruitment challenges[171]. - Modifications to clinical trial protocols, including changes to the low-dose administration prior to NKX019, may result in initial delays in patient enrollment[194]. - Adverse events reported in clinical trials, such as cytokine release syndrome, could negatively impact patient recruitment and retention[208]. - The FDA may apply a different benefit-risk threshold for autoimmune diseases compared to oncology, potentially affecting the approval of product candidates[209]. - Unacceptable side effects could lead to the suspension or termination of clinical trials, impacting the company's ability to develop and commercialize its product candidates[210]. Manufacturing and Supply Chain - The company has two cGMP facilities in South San Francisco, California, to support clinical supply and potential commercial supply of NKX019 and future product candidates[25]. - The NK cell engineering platform utilizes healthy donor NK cells, providing a diverse repertoire and abundant supply for manufacturing[26]. - The ability to produce hundreds of doses from a single manufacturing run enhances scalability and consistency of NK cell therapies[48]. - The manufacturing process aims for scalability and cost-effectiveness, ensuring consistent potency of CAR NK cells post-thawing[71]. - Manufacturing capabilities are critical for the timely supply of product candidates for clinical trials, and any delays could hinder patient treatment and trial completion[196]. - The company anticipates incurring significant costs associated with commercializing any approved product candidate, which could exceed current expectations if additional clinical trials are required by regulatory authorities[157]. Financial Performance - The company reported net losses of $104.1 million and $108.8 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $648.3 million as of December 31, 2025[152]. - The company has not generated any revenue from product sales and does not anticipate doing so until regulatory approvals are obtained for its product candidates[154]. - The company expects to continue incurring significant operating losses as it develops NKX019 and other product candidates, with anticipated increases in expenses related to clinical development and manufacturing[152]. - The company reported research and development expenses of $96.7 million for the year ended December 31, 2024, and $90.4 million for the year ended December 31, 2025[159]. - The company may need to raise additional capital to advance NKX019 into pivotal trials, which could lead to dilution for existing stockholders[159]. - The company has no commitments for additional financing and may need to raise funds through the sale of additional securities, which could adversely affect stockholder rights[160]. - The company recorded an impairment charge during the year ended December 31, 2025, due to a sustained decline in the trading price of its common stock[163]. - The company may face challenges in achieving profitability due to the competitive landscape and the need for substantial additional development time and resources[154]. Regulatory Environment - The company is subject to significant regulatory scrutiny, including the impact of the Inflation Reduction Act of 2022 on drug pricing and reimbursement[136]. - Compliance with government regulations for manufacturing requires substantial capital and technical expertise, with potential delays impacting development and commercialization[77]. - The FDA typically takes 30 days to review IND submissions, but this period can be extended if concerns arise, potentially delaying clinical trials[91]. - The BLA submission process requires substantial preparation costs and includes a user fee; the FDA has 60 days to accept the application for filing[99]. - Standard review BLAs typically have a review timeline of ten months, while priority review applications are completed within six months[100]. - The FDA may require a REMS to ensure safe use of a product, which can increase approval costs significantly[102]. - The FDA can suspend biologics licenses if public health risks are identified, emphasizing the importance of manufacturing controls[112]. - After BLA approval, products may require official lot release, with the FDA conducting tests to ensure safety and effectiveness before distribution[113]. - Companies can seek expedited approval through fast track designation or breakthrough therapy designation, facilitating closer collaboration with the FDA[105][106]. - The Special Protocol Assessment process allows companies to agree with the FDA on clinical trial designs, which are generally binding unless significant issues arise[109]. - The Biologics Price Competition and Innovation Act of 2009 (BPCIA) allows for an abbreviated approval pathway for biosimilars, requiring no clinically meaningful differences in safety, purity, and potency compared to reference products[114]. - A reference biologic is granted 12 years of exclusivity from the time of first licensure, with no biosimilar applications allowed for four years post-licensure[115]. - The FDA imposes strict post-approval requirements, including recordkeeping, periodic reporting, and compliance with current Good Manufacturing Practices (cGMP)[117]. - Approved drugs are subject to ongoing FDA regulation, which includes potential enforcement actions if compliance is not maintained[119]. Intellectual Property - The patent portfolio includes at least 55 issued utility patents and 200 pending applications, with significant focus on NKX019 and NK cell engineering[79]. - The company has exclusive rights to certain patents related to NK cell technology, with potential milestone payments up to 5 million Singapore Dollars[83]. - The company is actively working to maintain and expand its intellectual property portfolio while navigating the complexities of commercialization and regulatory approval processes[155]. Competition and Market Landscape - The company is focused on developing NKX019 for multiple B-cell driven autoimmune diseases, facing competition from various biopharmaceutical companies and research institutions[141]. - The development and commercialization of new cellular immunotherapy products is highly competitive, with significant competition from both biopharmaceutical companies and academic institutions[211]. - The company faced significant challenges in enrolling patients for its NKX019 clinical trials due to competition from other therapies targeting CD19, leading to deprioritization of the Phase 1 NKX019 program for B-cell malignancies[192]. - Third-party payors are increasingly scrutinizing the cost-effectiveness of products, which may require additional pharmaco-economic studies for reimbursement[124]. - Legislative changes in healthcare reform continue to evolve, impacting the pharmaceutical and biotechnology industry’s operational landscape[133].

Financial Performance - Comstock achieved revenues of $1.4 million in 2025, a 250% increase compared to $0.4 million in 2024, with total billings exceeding $3.5 million[23] - Cash and cash equivalents were reported at $17.0 million as of December 31, 2025, and increased to $56.1 million by March 20, 2026[7] - The company eliminated all debt obligations, resulting in a strong financial position for accelerating growth and monetizing non-core assets[7] Capital and Investments - The company completed an oversubscribed equity financing of $57.5 million in gross proceeds, strengthening its capital base for the commercialization of its metals recycling and refining processes[7] - Bioleum Corporation, a subsidiary, received $35 million in direct strategic investments from Marathon Petroleum Corp and another investor, enhancing its operational capabilities[14] Operations and Facilities - Comstock secured all permits for its first industry-scale facility, which is designed to recycle up to 3.3 million solar panels annually, with operations expected to commence in Q2 2026[19] - The company plans to monetize its legacy mineral and mining properties, with a focus on partnerships to develop and advance these assets[25] - Comstock aims to set the global standard for solar panel recycling, with a zero-landfill process and clean recycled products[16] - The company is actively pursuing additional Master Service Agreements with national and regional customers to expand its market presence[28] Risks and Uncertainties - The company emphasizes that all statements made are forward-looking and subject to risks and uncertainties[38] - Key risks include market conditions, demand for products, and operational challenges related to resource exploration and development[38] - The company anticipates potential changes in capital expenditures and their impact on financial performance[38] - Future financial performance may be influenced by the ability to commercialize new technologies and manage operational costs[38] - The company highlights the importance of compliance with regulatory requirements and the potential impact of legal changes on operations[38] - There is a focus on the potential effects of global economic uncertainties and geopolitical events on business operations[38] - The company acknowledges the risks associated with equipment failures and production capability interruptions[38] - Future employment and contributions of key personnel are critical to the company's operational success[38] - The company may face challenges in raising additional capital and securing financing[38] - The occurrence of unforeseen events could materially affect the company's financial condition and market price of securities[38] Governance - Comstock's board was expanded with three independent directors, reflecting support from two of the company's top four shareholders[7]